) FR940405-1-00081 3 1197 1207 1220
, FR940405-1-00081 4 1198 1208 1215 1217
the FR940405-1-00081 2 1199 1210
tissue FR940405-1-00081 1 1200
distribution FR940405-1-00081 1 1201
parameters FR940405-1-00081 2 1202 1212
( FR940405-1-00081 2 1203 1213
partitioning FR940405-1-00081 1 1204
and FR940405-1-00081 3 1205 1209 1218
binding FR940405-1-00081 1 1206
kinetic FR940405-1-00081 1 1211
absorption FR940405-1-00081 1 1214
metabolism FR940405-1-00081 1 1216
clearance FR940405-1-00081 1 1219
. FR940405-1-00081 1 1221
( FR940405-1-00082 5 0 10 27 44 394
a FR940405-1-00082 17 1 101 131 178 215 226 263 287 296 333 453 481 516 550 621 711 728
) FR940405-1-00082 5 2 12 29 46 396
physiological FR940405-1-00082 7 3 7 92 134 330 357 564
parameters FR940405-1-00082 7 4 8 358 387 398 428 541
. FR940405-1-00082 38 5 51 64 123 145 154 168 191 194 207 237 258 275 301 304 332 346 390 393 399 425 442 462 476 507 527 548 596 617 620 639 668 671 697 720 763 770 807
the FR940405-1-00082 64 6 13 17 20 30 47 60 70 79 82 85 91 97 110 113 120 146 161 169 185 199 205 210 219 234 242 246 259 269 276 320 328 356 383 403 408 415 426 430 443 448 463 500 508 519 530 539 557 563 573 583 601 604 630 643 648 656 659 674 700 716 753 785 805
include FR940405-1-00082 2 9 282
1 FR940405-1-00082 1 11
body FR940405-1-00082 1 14
weight FR940405-1-00082 1 15
and FR940405-1-00082 22 16 34 43 69 109 116 128 136 150 166 198 254 374 385 472 566 594 611 653 735 745 789
weights FR940405-1-00082 1 18
of FR940405-1-00082 36 19 84 88 96 112 143 148 172 187 245 251 256 313 402 417 484 492 505 510 512 521 544 559 577 590 603 632 637 642 645 655 661 702 713 756 778
individual FR940405-1-00082 1 21
organs FR940405-1-00082 2 22 253
or FR940405-1-00082 3 23 39 315
tissue FR940405-1-00082 7 24 40 182 231 409 635 792
groups FR940405-1-00082 3 25 107 248
, FR940405-1-00082 29 26 42 66 94 108 163 165 197 209 285 318 407 468 479 529 553 582 650 652 673 678 699 734 738 744 765 767 773 788
2 FR940405-1-00082 1 28
total FR940405-1-00082 2 31 689
blood FR940405-1-00082 2 32 593
flow FR940405-1-00082 2 33 117
flows FR940405-1-00082 1 35
to FR940405-1-00082 18 36 267 294 308 327 341 437 457 496 534 549 607 687 710 752 759 771 798
each FR940405-1-00082 2 37 580
organ FR940405-1-00082 1 38
group FR940405-1-00082 1 41
3 FR940405-1-00082 1 45
alveolar FR940405-1-00082 1 48
ventilation FR940405-1-00082 1 49
rate FR940405-1-00082 1 50
these FR940405-1-00082 6 52 173 238 513 525 664
quantities FR940405-1-00082 1 53
have FR940405-1-00082 2 54 799
been FR940405-1-00082 5 55 292 723 782 800
reasonably FR940405-1-00082 1 56
well FR940405-1-00082 2 57 373
established FR940405-1-00082 1 58
for FR940405-1-00082 11 59 90 126 160 272 466 488 524 579 715 732
human FR940405-1-00082 4 61 80 405 786
[ FR940405-1-00082 9 62 152 192 299 388 474 615 666 761
exs FR940405-1-00082 2 63 762
4155 FR940405-1-00082 1 65
4309 FR940405-1-00082 1 67
] FR940405-1-00082 9 68 156 196 303 392 478 619 670 769
chief FR940405-1-00082 1 71
effort FR940405-1-00082 1 72
associated FR940405-1-00082 5 73 561 626 682 739
with FR940405-1-00082 9 74 119 204 348 562 572 627 683 740
pharmacokinetic FR940405-1-00082 4 75 575 613 776
model FR940405-1-00082 16 76 147 186 221 236 261 279 306 343 366 380 432 546 584 606 787
parameterization FR940405-1-00082 1 77
in FR940405-1-00082 22 78 140 184 203 218 233 249 355 400 423 429 447 459 518 542 570 588 592 647 663 784 804
is FR940405-1-00082 9 81 201 213 223 569 629 685 727 750
determination FR940405-1-00082 1 83
necessary FR940405-1-00082 2 86 321
level FR940405-1-00082 2 87 483
detail FR940405-1-00082 1 89
description FR940405-1-00082 4 93 103 312 641
grouping FR940405-1-00082 1 95
tissues FR940405-1-00082 6 98 144 174 461 665 760
not FR940405-1-00082 4 99 281 376 796
meriting FR940405-1-00082 1 100
separate FR940405-1-00082 3 102 158 216
into FR940405-1-00082 3 104 177 225
pharmacokinetically FR940405-1-00082 2 105 633
similar FR940405-1-00082 3 106 297 482
association FR940405-1-00082 1 111
proper FR940405-1-00082 1 114
volume FR940405-1-00082 3 115 558 576
data FR940405-1-00082 5 118 441 465 514 614
selected FR940405-1-00082 1 121
groupings FR940405-1-00082 1 122
existing FR940405-1-00082 2 124 329
models FR940405-1-00082 3 125 406 450
nicotine FR940405-1-00082 8 127 493 610 638 646 684 733 757
cotinine FR940405-1-00082 6 129 467 489 506 612 737
contain FR940405-1-00082 2 130 309
fairly FR940405-1-00082 1 132
detailed FR940405-1-00082 1 133
structure FR940405-1-00082 2 135 565
differ FR940405-1-00082 2 137 451
only FR940405-1-00082 1 138
slightly FR940405-1-00082 1 139
their FR940405-1-00082 1 141
assignment FR940405-1-00082 1 142
plowchalk FR940405-1-00082 3 149 235 278
debethizy FR940405-1-00082 1 151
ex FR940405-1-00082 7 153 193 300 389 475 616 667
4254 FR940405-1-00082 1 155
includes FR940405-1-00082 1 157
compartments FR940405-1-00082 1 159
brain FR940405-1-00082 3 162 649 806
heart FR940405-1-00082 2 164 654
skin FR940405-1-00082 2 167 200
first FR940405-1-00082 1 170
two FR940405-1-00082 3 171 449 456
are FR940405-1-00082 3 175 370 375
lumped FR940405-1-00082 3 176 202 224
`` FR940405-1-00082 2 179 227
vesselrich FR940405-1-00082 1 180
'' FR940405-1-00082 2 181 230
compartment FR940405-1-00082 6 183 217 232 266 289 336
robinson FR940405-1-00082 5 188 220 260 431 605
et FR940405-1-00082 1 189
al FR940405-1-00082 1 190
4270 FR940405-1-00082 2 195 618
muscle FR940405-1-00082 1 206
conversely FR940405-1-00082 1 208
gastrointestinal FR940405-1-00082 1 211
tract FR940405-1-00082 1 212
given FR940405-1-00082 1 214
but FR940405-1-00082 3 222 286 319
slowly FR940405-1-00082 1 228
perfused FR940405-1-00082 1 229
differences FR940405-1-00082 1 239
mainly FR940405-1-00082 1 240
reflect FR940405-1-00082 1 241
different FR940405-1-00082 1 243
interests FR940405-1-00082 1 244
modeling FR940405-1-00082 2 247 523
terms FR940405-1-00082 3 250 543 589
target FR940405-1-00082 1 252
routes FR940405-1-00082 1 255
exposure FR940405-1-00082 3 257 317 714
contains FR940405-1-00082 1 262
venous FR940405-1-00082 1 264
infusion FR940405-1-00082 3 265 491 504
accommodate FR940405-1-00082 1 268
mixing FR940405-1-00082 1 270
time FR940405-1-00082 1 271
arterial FR940405-1-00082 1 273
administration FR940405-1-00082 1 274
published FR940405-1-00082 3 277 404 609
does FR940405-1-00082 2 280 795
this FR940405-1-00082 4 283 597 747 779
feature FR940405-1-00082 1 284
forearm FR940405-1-00082 1 288
has FR940405-1-00082 5 290 351 360 722 781
since FR940405-1-00082 1 291
added FR940405-1-00082 3 293 326 340
provide FR940405-1-00082 1 295
function FR940405-1-00082 1 298
483 FR940405-1-00082 1 302
neither FR940405-1-00082 1 305
appears FR940405-1-00082 1 307
an FR940405-1-00082 1 310
explicit FR940405-1-00082 1 311
inhalation FR940405-1-00082 1 314
oral FR940405-1-00082 1 316
equations FR940405-1-00082 1 322
could FR940405-1-00082 3 323 337 708
easily FR940405-1-00082 1 324
be FR940405-1-00082 3 325 339 535
structures FR940405-1-00082 1 331
salivary FR940405-1-00082 1 334
fluid FR940405-1-00082 1 335
also FR940405-1-00082 1 338
either FR940405-1-00082 1 342
if FR940405-1-00082 1 344
desired FR940405-1-00082 1 345
experience FR940405-1-00082 1 347
other FR940405-1-00082 2 349 439
chemicals FR940405-1-00082 2 350 526
shown FR940405-1-00082 1 352
that FR940405-1-00082 3 353 725 746
uncertainty FR940405-1-00082 4 354 367 485 625
generally FR940405-1-00082 1 359
much FR940405-1-00082 1 361
less FR940405-1-00082 2 362 536
impact FR940405-1-00082 1 363
on FR940405-1-00082 3 364 379 414
overall FR940405-1-00082 2 365 545
because FR940405-1-00082 1 368
they FR940405-1-00082 1 369
known FR940405-1-00082 1 371
relatively FR940405-1-00082 2 372 675
as FR940405-1-00082 4 377 382 554 556
influential FR940405-1-00082 1 378
behavior FR940405-1-00082 1 381
distribution FR940405-1-00082 4 384 560 578 628
kinetic FR940405-1-00082 2 386 540
456 FR940405-1-00082 1 391
b FR940405-1-00082 1 395
distributional FR940405-1-00082 1 397
both FR940405-1-00082 1 401
partitioning FR940405-1-00082 3 410 427 464
was FR940405-1-00082 2 411 598
initially FR940405-1-00082 1 412
estimated FR940405-1-00082 1 413
basis FR940405-1-00082 1 416
steadystate FR940405-1-00082 1 418
tissue/blood FR940405-1-00082 1 419
concentration FR940405-1-00082 1 420
ratios FR940405-1-00082 1 421
measured FR940405-1-00082 1 422
animals FR940405-1-00082 1 424
were FR940405-1-00082 2 433 494
then FR940405-1-00082 1 434
iteratively FR940405-1-00082 1 435
adjusted FR940405-1-00082 1 436
fit FR940405-1-00082 1 438
timecourse FR940405-1-00082 2 440 644
resulting FR940405-1-00082 1 444
partition FR940405-1-00082 3 445 531 567
coefficients FR940405-1-00082 3 446 532 568
by FR940405-1-00082 3 452 470 600
factor FR940405-1-00082 1 454
from FR940405-1-00082 1 455
five FR940405-1-00082 1 458
corresponding FR940405-1-00082 1 460
determined FR940405-1-00082 1 469
gabrelsson FR940405-1-00082 1 471
bondesson FR940405-1-00082 1 473
4112 FR940405-1-00082 1 477
show FR940405-1-00082 1 480
; FR940405-1-00082 1 486
partitions FR940405-1-00082 2 487 502
following FR940405-1-00082 2 490 503
two- FR940405-1-00082 1 495
fivefold FR940405-1-00082 1 497
higher FR940405-1-00082 1 498
than FR940405-1-00082 2 499 538
same FR940405-1-00082 1 501
lack FR940405-1-00082 1 509
reproducibility FR940405-1-00082 1 511
represents FR940405-1-00082 1 515
deficiency FR940405-1-00082 1 517
development FR940405-1-00082 1 520
pbpk FR940405-1-00082 1 522
fortunately FR940405-1-00082 1 528
tend FR940405-1-00082 1 533
important FR940405-1-00082 1 537
performance FR940405-1-00082 1 547
large FR940405-1-00082 1 551
extent FR940405-1-00082 1 552
long FR940405-1-00082 1 555
agreement FR940405-1-00082 1 571
apparent FR940405-1-00082 1 574
chemical FR940405-1-00082 1 581
will FR940405-1-00082 1 585
perform FR940405-1-00082 1 586
adequately FR940405-1-00082 1 587
timecourses FR940405-1-00082 1 591
urine FR940405-1-00082 1 595
evidenced FR940405-1-00082 1 599
ability FR940405-1-00082 1 602
reproduce FR940405-1-00082 1 608
potentially FR940405-1-00082 1 622
more FR940405-1-00082 1 623
significant FR940405-1-00082 2 624 634
possibility FR940405-1-00082 2 631 780
binding FR940405-1-00082 4 636 662 681 793
satisfactory FR940405-1-00082 1 640
lung FR940405-1-00082 1 651
rat FR940405-1-00082 1 657
required FR940405-1-00082 1 658
inclusion FR940405-1-00082 1 660
4255 FR940405-1-00082 1 669
clearly FR940405-1-00082 1 672
low FR940405-1-00082 4 676 695 706 741
capacity FR940405-1-00082 1 677
high FR940405-1-00082 1 679
affinity FR940405-1-00082 1 680
unlikely FR940405-1-00082 1 686
effect FR940405-1-00082 1 688
systemic FR940405-1-00082 1 690
clearance FR940405-1-00082 2 691 730
except FR940405-1-00082 2 692 802
at FR940405-1-00082 2 693 705
very FR940405-1-00082 1 694
concentrations FR940405-1-00082 3 696 707 743
however FR940405-1-00082 1 698
existence FR940405-1-00082 1 701
nonlinear FR940405-1-00082 1 703
pharmacokinetics FR940405-1-00082 1 704
lead FR940405-1-00082 1 709
miscalculation FR940405-1-00082 1 712
least FR940405-1-00082 1 717
exposed FR940405-1-00082 1 718
individuals FR940405-1-00082 1 719
it FR940405-1-00082 1 721
suggested FR940405-1-00082 1 724
there FR940405-1-00082 1 726
longer FR940405-1-00082 2 729 748
halflife FR940405-1-00082 2 731 749
therefore FR940405-1-00082 1 736
circulating FR940405-1-00082 1 742
due FR940405-1-00082 1 751
slower FR940405-1-00082 1 754
release FR940405-1-00082 1 755
bound FR940405-1-00082 1 758
428 FR940405-1-00082 1 764
424 FR940405-1-00082 1 766
4167 FR940405-1-00082 1 768
date FR940405-1-00082 1 772
no FR940405-1-00082 1 774
careful FR940405-1-00082 1 775
investigation FR940405-1-00082 1 777
performed FR940405-1-00082 1 783
adequate FR940405-1-00082 1 790
nicotinespecific FR940405-1-00082 1 791
information FR940405-1-00082 1 794
appear FR940405-1-00082 1 797
collected FR940405-1-00082 1 801
perhaps FR940405-1-00082 1 803
( FR940405-1-00083 5 0 260 459 462 478
c FR940405-1-00083 1 1
) FR940405-1-00083 5 2 264 461 464 480
kinetic FR940405-1-00083 3 3 172 341
parameters FR940405-1-00083 8 4 11 54 124 151 162 173 342
. FR940405-1-00083 21 5 29 45 72 108 144 166 183 210 221 265 282 294 329 351 396 441 448 465 558 565
by FR940405-1-00083 2 6 57
far FR940405-1-00083 1 7
the FR940405-1-00083 41 8 13 18 30 46 61 73 86 100 110 122 128 146 149 160 168 171 187 191 222 243 248 269 298 301 312 321 340 344 354 379 386 402 425 429 467 471 482 517 524 544
most FR940405-1-00083 1 9
significant FR940405-1-00083 3 10 418 552
in FR940405-1-00083 15 12 70 105 145 167 197 206 226 278 289 300 365 384 424 466
models FR940405-1-00083 2 14 361
are FR940405-1-00083 1 15
those FR940405-1-00083 2 16 103
describing FR940405-1-00083 2 17 174
absorption FR940405-1-00083 1 19
, FR940405-1-00083 38 20 22 81 84 125 135 139 152 157 163 176 186 212 214 216 218 230 236 241 262 287 297 308 309 320 324 326 327 412 445 452 457 470 484 511 516 521 529
metabolism FR940405-1-00083 1 21
and FR940405-1-00083 19 23 27 37 43 85 92 126 140 242 276 314 325 349 358 367 375 392 427 491
clearance FR940405-1-00083 6 24 39 65 134 175 346
of FR940405-1-00083 30 25 48 63 89 102 121 133 137 142 148 170 194 224 233 245 251 268 274 303 316 318 334 347 356 381 399 420 481 526 554
nicotine FR940405-1-00083 6 26 42 91 275 319 348
cotinine FR940405-1-00083 8 28 44 93 195 277 293 306 350
robinson FR940405-1-00083 1 31
model FR940405-1-00083 4 32 50 75 111
uses FR940405-1-00083 1 33
reported FR940405-1-00083 5 34 64 196 252 290
human FR940405-1-00083 2 35 106
hepatic FR940405-1-00083 1 36
renal FR940405-1-00083 2 38 345
values FR940405-1-00083 4 40 66 189 254
for FR940405-1-00083 13 41 77 159 184 190 247 292 295 305 311 339 343 371
sensitivity FR940405-1-00083 1 47
this FR940405-1-00083 2 49 382
to FR940405-1-00083 8 51 96 119 203 394 435 504 542
these FR940405-1-00083 2 52 227
input FR940405-1-00083 2 53 123
was FR940405-1-00083 3 55 307 323
investigated FR940405-1-00083 1 56
varying FR940405-1-00083 1 58
them FR940405-1-00083 1 59
within FR940405-1-00083 2 60 99
range FR940405-1-00083 2 62 200
from FR940405-1-00083 3 67 201 238
infusion FR940405-1-00083 2 68 273
studies FR940405-1-00083 4 69 107 199 229
humans FR940405-1-00083 2 71 279
resulting FR940405-1-00083 1 74
predictions FR940405-1-00083 1 76
postn FR940405-1-00083 1 78
blood FR940405-1-00083 1 79
levels FR940405-1-00083 1 80
urinary FR940405-1-00083 1 82
output FR940405-1-00083 1 83
elimination FR940405-1-00083 2 87 143
halflives FR940405-1-00083 2 88 291
both FR940405-1-00083 1 90
were FR940405-1-00083 1 94
found FR940405-1-00083 2 95 285
be FR940405-1-00083 2 97 337
well FR940405-1-00083 1 98
ranges FR940405-1-00083 2 101 237
observed FR940405-1-00083 1 104
thus FR940405-1-00083 1 109
structure FR940405-1-00083 1 112
does FR940405-1-00083 1 113
not FR940405-1-00083 2 114 538
produce FR940405-1-00083 1 115
an FR940405-1-00083 3 116 330 362
exaggerated FR940405-1-00083 1 117
response FR940405-1-00083 1 118
variation FR940405-1-00083 6 120 225 246 288 299 322
reflects FR940405-1-00083 1 127
natural FR940405-1-00083 1 129
interaction FR940405-1-00083 1 130
between FR940405-1-00083 2 131 388
measures FR940405-1-00083 1 132
volume FR940405-1-00083 3 136 302 315
distribution FR940405-1-00083 3 138 304 317
rates FR940405-1-00083 1 141
case FR940405-1-00083 3 147 169 469
physiological FR940405-1-00083 1 150
variability FR940405-1-00083 4 153 180 235 335
dominates FR940405-1-00083 3 154 165 182
over FR940405-1-00083 1 155
uncertainty FR940405-1-00083 2 156 164
while FR940405-1-00083 2 158 310
distributional FR940405-1-00083 1 161
it FR940405-1-00083 2 177 531
appears FR940405-1-00083 1 178
that FR940405-1-00083 8 179 416 428 439 475 510 530 539
again FR940405-1-00083 1 181
example FR940405-1-00083 1 185
mean FR940405-1-00083 1 188
terminal FR940405-1-00083 1 192
halflife FR940405-1-00083 2 193 313
different FR940405-1-00083 1 198
12 FR940405-1-00083 1 202
21 FR940405-1-00083 1 204
hours FR940405-1-00083 1 205
nons FR940405-1-00083 1 207
[ FR940405-1-00083 3 208 280 543
exs FR940405-1-00083 1 209
424 FR940405-1-00083 1 211
473 FR940405-1-00083 1 213
482 FR940405-1-00083 1 215
4184 FR940405-1-00083 1 217
4186 FR940405-1-00083 1 219
] FR940405-1-00083 3 220 284 549
coefficient FR940405-1-00083 2 223 244
same FR940405-1-00083 1 228
a FR940405-1-00083 8 231 266 286 417 487 496 514 551
measure FR940405-1-00083 1 232
interindividual FR940405-1-00083 1 234
1722 FR940405-1-00083 1 239
% FR940405-1-00083 2 240 259
entire FR940405-1-00083 1 249
collection FR940405-1-00083 1 250
individual FR940405-1-00083 1 253
is FR940405-1-00083 4 255 422 432 532
similar FR940405-1-00083 1 256
: FR940405-1-00083 1 257
22 FR940405-1-00083 1 258
n=35 FR940405-1-00083 1 261
mean=16.2 FR940405-1-00083 1 263
review FR940405-1-00083 1 267
published FR940405-1-00083 1 270
data FR940405-1-00083 1 271
on FR940405-1-00083 3 272 378 523
ex FR940405-1-00083 1 281
4270 FR940405-1-00083 1 283
comparison FR940405-1-00083 1 296
respectively FR940405-1-00083 1 328
even FR940405-1-00083 1 331
greater FR940405-1-00083 1 332
level FR940405-1-00083 1 333
can FR940405-1-00083 2 336 404
expected FR940405-1-00083 1 338
osha FR940405-1-00083 1 352
considers FR940405-1-00083 1 353
use FR940405-1-00083 1 355
pharmacokinetics FR940405-1-00083 1 357
specifically FR940405-1-00083 1 359
pbpk FR940405-1-00083 1 360
important FR940405-1-00083 1 363
tool FR940405-1-00083 1 364
characterizing FR940405-1-00083 1 366
quantifying FR940405-1-00083 1 368
internal FR940405-1-00083 1 369
dose FR940405-1-00083 1 370
evaluation FR940405-1-00083 1 372
potential FR940405-1-00083 1 373
exposures FR940405-1-00083 1 374
seeks FR940405-1-00083 1 376
comment FR940405-1-00083 1 377
applicability FR940405-1-00083 1 380
approach FR940405-1-00083 1 383
ascertaining FR940405-1-00083 1 385
relationship FR940405-1-00083 1 387
adverse FR940405-1-00083 1 389
health FR940405-1-00083 5 390 408 492 508 556
effects FR940405-1-00083 1 391
exposure FR940405-1-00083 2 393 541
ets FR940405-1-00083 1 395
v. FR940405-1-00083 1 397
significance FR940405-1-00083 1 398
risk FR940405-1-00083 4 400 419 440 553
before FR940405-1-00083 2 401 512
secretary FR940405-1-00083 2 403 518
promulgate FR940405-1-00083 1 405
any FR940405-1-00083 1 406
permanent FR940405-1-00083 1 407
or FR940405-1-00083 4 409 437 501 507
safety FR940405-1-00083 3 410 490 506
standard FR940405-1-00083 4 411 431 493 515
he FR940405-1-00083 1 413
must FR940405-1-00083 2 414 519
find FR940405-1-00083 2 415 520
harm FR940405-1-00083 1 421
present FR940405-1-00083 1 423
workplace FR940405-1-00083 1 426
new FR940405-1-00083 2 430 547
reasonably FR940405-1-00083 2 433 499
necessary FR940405-1-00083 2 434 500
reduce FR940405-1-00083 1 436
eliminate FR940405-1-00083 1 438
industrial FR940405-1-00083 1 442
union FR940405-1-00083 1 443
department FR940405-1-00083 1 444
aflcio FR940405-1-00083 1 446
v FR940405-1-00083 1 447
american FR940405-1-00083 1 449
petroleum FR940405-1-00083 1 450
institute FR940405-1-00083 1 451
444 FR940405-1-00083 2 453 560
u. FR940405-1-00083 2 454 561
s. FR940405-1-00083 2 455 562
607 FR940405-1-00083 1 456
639642 FR940405-1-00083 1 458
1980 FR940405-1-00083 1 460
benzene FR940405-1-00083 2 463 468
supreme FR940405-1-00083 1 472
court FR940405-1-00083 1 473
held FR940405-1-00083 1 474
section FR940405-1-00083 1 476
3 FR940405-1-00083 1 477
8 FR940405-1-00083 1 479
act FR940405-1-00083 1 483
which FR940405-1-00083 1 485
defines FR940405-1-00083 1 486
`` FR940405-1-00083 3 488 497 522
occupational FR940405-1-00083 1 489
'' FR940405-1-00083 3 494 503 559
as FR940405-1-00083 1 495
requirement FR940405-1-00083 1 498
appropriate FR940405-1-00083 1 502
promote FR940405-1-00083 1 505
requires FR940405-1-00083 1 509
promulgating FR940405-1-00083 1 513
basis FR940405-1-00083 1 525
substantial FR940405-1-00083 1 527
evidence FR940405-1-00083 1 528
at FR940405-1-00083 2 533 563
least FR940405-1-00083 1 534
more FR940405-1-00083 1 535
likely FR940405-1-00083 1 536
than FR940405-1-00083 1 537
longterm FR940405-1-00083 1 540
hazard FR940405-1-00083 1 545
without FR940405-1-00083 1 546
regulation FR940405-1-00083 1 548
presents FR940405-1-00083 1 550
material FR940405-1-00083 1 555
impairment FR940405-1-00083 1 557
653 FR940405-1-00083 1 564
in FR940405-1-00084 30 0 37 72 109 262 292 311 333 347 370 386 389 434 439 472 586 629 661 680 688 705 717 884 975 979 998 1003 1077 1160 1216
the FR940405-1-00084 70 1 5 15 25 31 38 68 90 100 105 133 138 166 204 219 232 246 256 263 267 293 312 323 342 359 371 374 391 394 403 413 418 428 440 479 506 514 527 543 562 587 634 639 647 655 662 670 681 730 735 744 749 753 807 839 872 901 950 976 993 1008 1070 1078 1107 1110 1114 1161 1217 1222 1246
benzene FR940405-1-00084 4 2 122 324 375
decision FR940405-1-00084 1 3
, FR940405-1-00084 53 4 64 67 89 103 126 152 185 191 200 302 322 358 388 402 437 484 504 523 596 624 638 683 686 752 767 774 776 799 816 853 871 935 961 990 996 1015 1021 1112 1133 1135 1137 1140 1148 1177 1191 1209 1211 1221 1264 1267 1271 1281
supreme FR940405-1-00084 1 6
court FR940405-1-00084 4 7 26 325 376
indicated FR940405-1-00084 2 8 327
when FR940405-1-00084 4 9 296 590 1012
a FR940405-1-00084 20 10 46 73 76 84 110 127 241 299 329 334 354 593 726 783 862 928 962 1103 1184
reasonable FR940405-1-00084 4 11 128 349 489
person FR940405-1-00084 3 12 77 129
might FR940405-1-00084 2 13 130
consider FR940405-1-00084 2 14 132
risk FR940405-1-00084 21 16 50 91 134 330 355 360 395 416 426 503 544 626 637 642 723 732 754 792 1207 1218
significant FR940405-1-00084 10 17 48 97 135 339 384 502 628 722 791
and FR940405-1-00084 26 18 57 136 178 277 340 427 447 458 501 571 608 631 747 818 844 861 867 943 981 1046 1118 1142 1167 1242 1273
take FR940405-1-00084 3 19 137 408
steps FR940405-1-00084 2 20 140
to FR940405-1-00084 37 21 35 44 141 173 208 210 235 290 351 368 407 424 456 470 490 497 536 551 584 617 620 650 659 678 703 724 734 781 877 886 891 913 1036 1054 1183 1292
decrease FR940405-1-00084 2 22 142
it FR940405-1-00084 11 23 29 42 145 485 665 777 800 804 906 1016
. FR940405-1-00084 47 24 51 62 98 146 150 159 189 198 212 239 261 295 318 356 385 433 477 519 538 561 589 622 646 664 697 715 733 760 793 811 832 869 918 947 986 1010 1027 1042 1067 1085 1122 1158 1189 1203 1245 1275
stated FR940405-1-00084 1 27
: FR940405-1-00084 2 28 1238
is FR940405-1-00084 21 30 194 251 405 495 525 554 627 643 685 763 778 801 848 907 959 972 1001 1017 1100 1119
agency FR940405-1-00084 7 32 268 343 493 507 563 1223
's FR940405-1-00084 6 33 258 377 719 988 1044
responsibility FR940405-1-00084 1 34
determine FR940405-1-00084 2 36 782
first FR940405-1-00084 1 39
instance FR940405-1-00084 1 40
what FR940405-1-00084 2 41 380
considers FR940405-1-00084 1 43
be FR940405-1-00084 14 45 95 124 273 337 345 382 488 568 676 701 711 757 806
`` FR940405-1-00084 7 47 222 784 883 905 1174 1282
'' FR940405-1-00084 7 49 230 787 904 912 1176 1285
some FR940405-1-00084 1 52
risks FR940405-1-00084 1 53
are FR940405-1-00084 16 54 59 70 107 119 175 454 461 694 739 940 1059 1124 1173 1194 1286
plainly FR940405-1-00084 2 55 60
acceptable FR940405-1-00084 1 56
others FR940405-1-00084 2 58 1117
unacceptable FR940405-1-00084 1 61
if FR940405-1-00084 3 63 104 795
for FR940405-1-00084 8 65 772 828 838 850 895 1204 1276
example FR940405-1-00084 1 66
odds FR940405-1-00084 2 69 106
one FR940405-1-00084 5 71 108 315 332 948
billion FR940405-1-00084 1 74
that FR940405-1-00084 20 75 112 118 270 328 341 443 459 492 542 558 565 684 737 788 796 847 882 1063 1164
will FR940405-1-00084 8 78 123 272 567 710 755 1038 1080
die FR940405-1-00084 1 79
from FR940405-1-00084 8 80 206 361 547 574 654 713 1089
cancer FR940405-1-00084 10 81 177 193 282 309 363 450 524 560 636
by FR940405-1-00084 4 82 397 668 992
taking FR940405-1-00084 1 83
drink FR940405-1-00084 1 85
of FR940405-1-00084 51 86 115 165 214 221 225 248 255 280 314 331 379 393 415 421 431 475 481 517 545 559 604 611 641 657 729 741 743 748 766 820 841 858 865 930 933 938 949 968 984 1007 1033 1095 1106 1109 1144 1170 1186 1200 1206 1278
chlorinated FR940405-1-00084 1 87
water FR940405-1-00084 3 88 969 977
clearly FR940405-1-00084 3 92 326 623
could FR940405-1-00084 3 93 336 381
not FR940405-1-00084 9 94 411 526 756 779 802 836 1013 1195
considered FR940405-1-00084 5 96 297 338 383 591
on FR940405-1-00084 4 99 478 1198 1227
other FR940405-1-00084 4 101 896 1047 1126
hand FR940405-1-00084 1 102
thousand FR940405-1-00084 4 111 317 335 615
regular FR940405-1-00084 1 113
inhalation FR940405-1-00084 1 114
gasoline FR940405-1-00084 1 116
vapors FR940405-1-00084 1 117
2 FR940405-1-00084 1 120
% FR940405-1-00084 4 121 1006 1032 1169
fatal FR940405-1-00084 5 125 197 211 1002 1014
well FR940405-1-00084 1 131
appropriate FR940405-1-00084 4 139 253 849 911
or FR940405-1-00084 6 143 227 237 894 910 1025
eliminate FR940405-1-00084 3 144 238 790
( FR940405-1-00084 3 147 181 1256
iud FR940405-1-00084 1 148
v FR940405-1-00084 1 149
api FR940405-1-00084 1 151
448 FR940405-1-00084 1 153
u. FR940405-1-00084 1 154
s. FR940405-1-00084 1 155
at FR940405-1-00084 2 156 244
655 FR940405-1-00084 1 157
) FR940405-1-00084 3 158 188 1260
a. FR940405-1-00084 1 160
environmental FR940405-1-00084 1 161
tobacco FR940405-1-00084 1 162
smoke FR940405-1-00084 2 163 679
two FR940405-1-00084 3 164 936 1228
adverse FR940405-1-00084 3 167 530 1127
health FR940405-1-00084 9 168 226 531 859 934 953 1061 1128 1229
effects FR940405-1-00084 10 169 432 518 860 954 1062 1129 1188 1202 1230
associated FR940405-1-00084 9 170 364 533 955 964 1049 1152 1232 1250
with FR940405-1-00084 12 171 365 534 633 900 956 965 1050 1069 1153 1233 1251
exposure FR940405-1-00084 7 172 367 535 553 619 658 775
ets FR940405-1-00084 11 174 291 369 457 471 537 552 585 621 660 714
lung FR940405-1-00084 7 176 192 281 308 362 449 635
heart FR940405-1-00084 6 179 183 201 548 575 612
disease FR940405-1-00084 11 180 184 202 549 576 613 963 989 1045 1115 1147
coronary FR940405-1-00084 1 182
excluding FR940405-1-00084 1 186
strokes FR940405-1-00084 1 187
clinically FR940405-1-00084 1 190
almost FR940405-1-00084 1 195
always FR940405-1-00084 1 196
however FR940405-1-00084 2 199 1210
runs FR940405-1-00084 1 203
gamut FR940405-1-00084 1 205
severe FR940405-1-00084 5 207 952 1020 1243 1283
disabling FR940405-1-00084 1 209
both FR940405-1-00084 1 213
these FR940405-1-00084 6 215 249 482 1083 1187 1201
diseases FR940405-1-00084 1 216
then FR940405-1-00084 1 217
constitute FR940405-1-00084 2 218 1064
type FR940405-1-00084 1 220
material FR940405-1-00084 3 223 931 1065
impairment FR940405-1-00084 2 224 1066
functional FR940405-1-00084 1 228
capacity FR940405-1-00084 1 229
which FR940405-1-00084 8 231 673 693 939 971 1000 1149 1180
act FR940405-1-00084 1 233
seeks FR940405-1-00084 2 234 649
reduce FR940405-1-00084 4 236 352 498 1082
therefore FR940405-1-00084 2 240 357
standard FR940405-1-00084 1 242
aimed FR940405-1-00084 1 243
reducing FR940405-1-00084 1 245
incidence FR940405-1-00084 1 247
impairments FR940405-1-00084 2 250 932
an FR940405-1-00084 5 252 306 600 706 769
exercise FR940405-1-00084 1 254
secretary FR940405-1-00084 3 257 404 874
regulatory FR940405-1-00084 1 259
authority FR940405-1-00084 1 260
case FR940405-1-00084 2 264 436
before FR940405-1-00084 1 265
us FR940405-1-00084 1 266
estimates FR940405-1-00084 3 269 540 564
there FR940405-1-00084 7 271 460 566 709 738 762 1123
approximately FR940405-1-00084 5 274 444 605 1004 1092
between FR940405-1-00084 5 275 445 569 606 1165
144 FR940405-1-00084 2 276 446
722 FR940405-1-00084 2 278 448
cases FR940405-1-00084 4 279 610 1009 1094
per FR940405-1-00084 5 283 316 452 577 614
year FR940405-1-00084 3 284 453 578
among FR940405-1-00084 2 285 579
nonsmoking FR940405-1-00084 4 286 466 580 652
american FR940405-1-00084 3 287 467 581
workers FR940405-1-00084 5 288 422 468 582 868
exposed FR940405-1-00084 5 289 423 469 583 1035
workplace FR940405-1-00084 8 294 313 372 400 588 618 663 682
over FR940405-1-00084 3 298 463 592
working FR940405-1-00084 2 300 594
lifetime FR940405-1-00084 2 301 595
this FR940405-1-00084 10 303 435 499 510 597 625 667 716 851 1099
translates FR940405-1-00084 2 304 598
into FR940405-1-00084 3 305 409 599
excess FR940405-1-00084 2 307 601
rate FR940405-1-00084 3 310 414 603
as FR940405-1-00084 7 319 520 1028 1030 1131 1212 1288
noted FR940405-1-00084 2 320 521
above FR940405-1-00084 2 321 522
would FR940405-1-00084 6 344 486 508 675 789 805
justified FR940405-1-00084 1 346
prescribing FR940405-1-00084 2 348 669
efforts FR940405-1-00084 1 350
such FR940405-1-00084 3 353 425 1130
worker FR940405-1-00084 1 366
meets FR940405-1-00084 1 373
characterization FR940405-1-00084 1 378
addition FR940405-1-00084 1 387
evaluating FR940405-1-00084 1 390
significance FR940405-1-00084 2 392 640
posed FR940405-1-00084 1 396
any FR940405-1-00084 1 398
particular FR940405-1-00084 1 399
hazard FR940405-1-00084 1 401
entitled FR940405-1-00084 1 406
consideration FR940405-1-00084 1 410
only FR940405-1-00084 4 412 528 687 725
but FR940405-1-00084 1 417
total FR940405-1-00084 1 419
number FR940405-1-00084 1 420
absolute FR940405-1-00084 1 429
magnitude FR940405-1-00084 2 430 516
evidence FR940405-1-00084 2 438 1159
record FR940405-1-00084 2 441 1162
shows FR940405-1-00084 1 442
deaths FR940405-1-00084 2 451 573
attributable FR940405-1-00084 1 455
presently FR940405-1-00084 1 462
74 FR940405-1-00084 1 464
million FR940405-1-00084 1 465
their FR940405-1-00084 1 473
places FR940405-1-00084 1 474
employment FR940405-1-00084 1 476
basis FR940405-1-00084 1 480
data FR940405-1-00084 2 483 1193
also FR940405-1-00084 1 487
conclude FR940405-1-00084 1 491
action FR940405-1-00084 1 494
warranted FR940405-1-00084 1 496
widespread FR940405-1-00084 1 500
although FR940405-1-00084 2 505 1098
reach FR940405-1-00084 1 509
conclusion FR940405-1-00084 1 511
even FR940405-1-00084 4 512 555 794 1011
without FR940405-1-00084 1 513
great FR940405-1-00084 2 515 645
serious FR940405-1-00084 3 529 1060 1290
effect FR940405-1-00084 1 532
preliminary FR940405-1-00084 1 539
indicate FR940405-1-00084 1 541
mortality FR940405-1-00084 1 546
due FR940405-1-00084 2 550 1053
greater FR940405-1-00084 2 556 888
than FR940405-1-00084 1 557
2094 FR940405-1-00084 1 570
13000 FR940405-1-00084 1 572
death FR940405-1-00084 1 602
7 FR940405-1-00084 1 607
16 FR940405-1-00084 1 609
attributed FR940405-1-00084 1 616
itself FR940405-1-00084 1 630
combined FR940405-1-00084 1 632
very FR940405-1-00084 2 644 1019
proposal FR940405-1-00084 2 648 1079
protect FR940405-1-00084 1 651
employees FR940405-1-00084 2 653 674
hazards FR940405-1-00084 1 656
does FR940405-1-00084 1 666
conditions FR940405-1-00084 1 671
under FR940405-1-00084 1 672
allowed FR940405-1-00084 1 677
separately FR940405-1-00084 2 689 695
enclosed FR940405-1-00084 1 690
designated FR940405-1-00084 1 691
areas FR940405-1-00084 1 692
ventilated FR940405-1-00084 1 696
no FR940405-1-00084 2 698 764
employee FR940405-1-00084 1 699
can FR940405-1-00084 1 700
required FR940405-1-00084 1 702
work FR940405-1-00084 1 704
area FR940405-1-00084 1 707
where FR940405-1-00084 1 708
contamination FR940405-1-00084 3 712 967 1052
osha FR940405-1-00084 1 718
view FR940405-1-00084 1 720
reduces FR940405-1-00084 1 721
small FR940405-1-00084 1 727
percentage FR940405-1-00084 1 728
current FR940405-1-00084 1 731
extent FR940405-1-00084 1 736
failures FR940405-1-00084 1 740
enforcement FR940405-1-00084 1 742
smoking FR940405-1-00084 1 745
limitation FR940405-1-00084 1 746
ventilation FR940405-1-00084 1 750
system FR940405-1-00084 1 751
totally FR940405-1-00084 1 758
eliminated FR940405-1-00084 1 759
since FR940405-1-00084 2 761 1113
definition FR940405-1-00084 1 765
nor FR940405-1-00084 1 768
established FR940405-1-00084 1 770
method FR940405-1-00084 1 771
quantifying FR940405-1-00084 1 773
possible FR940405-1-00084 2 780 798
dose FR940405-1-00084 1 785
limit FR940405-1-00084 1 786
were FR940405-1-00084 1 797
clear FR940405-1-00084 1 803
correct FR940405-1-00084 1 808
policy FR940405-1-00084 2 809 845
approach FR940405-1-00084 1 810
29 FR940405-1-00084 2 812 878
cfr FR940405-1-00084 2 813 879
part FR940405-1-00084 1 814
1990_identification FR940405-1-00084 1 815
classification FR940405-1-00084 1 817
regulation FR940405-1-00084 1 819
potential FR940405-1-00084 1 821
occupational FR940405-1-00084 2 822 830
carcinogens FR940405-1-00084 2 823 831
sets FR940405-1-00084 1 824
forth FR940405-1-00084 2 825 1076
certain FR940405-1-00084 1 826
procedures FR940405-1-00084 3 827 834 916
regulating FR940405-1-00084 1 829
those FR940405-1-00084 3 833 1034 1289
may FR940405-1-00084 2 835 1181
allow FR940405-1-00084 1 837
level FR940405-1-00084 1 840
public FR940405-1-00084 1 842
input FR940405-1-00084 1 843
review FR940405-1-00084 1 846
rulemaking FR940405-1-00084 1 852
involving FR940405-1-00084 1 854
many FR940405-1-00084 2 855 1029
different FR940405-1-00084 2 856 915
types FR940405-1-00084 1 857
broad FR940405-1-00084 1 863
range FR940405-1-00084 1 864
employers FR940405-1-00084 1 866
accordingly FR940405-1-00084 1 870
assistant FR940405-1-00084 1 873
finds FR940405-1-00084 1 875
pursuant FR940405-1-00084 1 876
section FR940405-1-00084 1 880
1911.4 FR940405-1-00084 1 881
order FR940405-1-00084 1 885
provide FR940405-1-00084 1 887
procedural FR940405-1-00084 1 889
protections FR940405-1-00084 1 890
interested FR940405-1-00084 1 892
persons FR940405-1-00084 1 893
good FR940405-1-00084 1 897
cause FR940405-1-00084 1 898
consistent FR940405-1-00084 1 899
applicable FR940405-1-00084 1 902
laws FR940405-1-00084 1 903
found FR940405-1-00084 2 908 974
necessary FR940405-1-00084 1 909
adopt FR940405-1-00084 1 914
here FR940405-1-00084 1 917
b. FR940405-1-00084 1 919
indoor FR940405-1-00084 7 920 924 1056 1071 1155 1235 1253
air FR940405-1-00084 7 921 925 1057 1072 1156 1236 1254
quality FR940405-1-00084 7 922 926 1058 1073 1157 1237 1255
poor FR940405-1-00084 5 923 1055 1154 1234 1252
creates FR940405-1-00084 1 927
variety FR940405-1-00084 2 929 1185
aspects FR940405-1-00084 1 937
buildingrelated FR940405-1-00084 2 941 957
illness FR940405-1-00084 2 942 958
sick FR940405-1-00084 4 944 1040 1175 1257
building FR940405-1-00084 2 945 1258
syndrome FR940405-1-00084 2 946 1259
most FR940405-1-00084 2 951 1101
legionellosis FR940405-1-00084 1 960
microbial FR940405-1-00084 2 966 1051
sources FR940405-1-00084 1 970
commonly FR940405-1-00084 2 973 1231
present FR940405-1-00084 1 978
heating FR940405-1-00084 1 980
cooling FR940405-1-00084 1 982
systems FR940405-1-00084 1 983
buildings FR940405-1-00084 2 985 1172
legionnaire FR940405-1-00084 2 987 1043
caused FR940405-1-00084 1 991
legionella FR940405-1-00084 3 994 1037 1096
organism FR940405-1-00084 1 995
results FR940405-1-00084 1 997
pneumonia FR940405-1-00084 1 999
20 FR940405-1-00084 2 1005 1166
usually FR940405-1-00084 1 1018
requiring FR940405-1-00084 1 1022
substantial FR940405-1-00084 1 1023
treatment FR940405-1-00084 1 1024
hospitalization FR940405-1-00084 1 1026
5 FR940405-1-00084 1 1031
get FR940405-1-00084 1 1039
1 FR940405-1-00084 2 1041 1086
illnesses FR940405-1-00084 2 1048 1084
compliance FR940405-1-00084 1 1068
provisions FR940405-1-00084 1 1074
set FR940405-1-00084 1 1075
substantially FR940405-1-00084 1 1081
raw FR940405-1-00084 1 1087
figures FR940405-1-00084 1 1088
1992 FR940405-1-00084 1 1090
show FR940405-1-00084 1 1091
1300 FR940405-1-00084 1 1093
reported FR940405-1-00084 1 1097
certainly FR940405-1-00084 1 1102
gross FR940405-1-00084 1 1104
undern FR940405-1-00084 1 1105
scope FR940405-1-00084 1 1108
problem FR940405-1-00084 1 1111
resembles FR940405-1-00084 1 1116
frequently FR940405-1-00084 1 1120
misdiagnosed FR940405-1-00084 1 1121
numerous FR940405-1-00084 1 1125
nausea FR940405-1-00084 1 1132
dizziness FR940405-1-00084 1 1134
fatigue FR940405-1-00084 1 1136
pulmonary FR940405-1-00084 1 1138
edema FR940405-1-00084 1 1139
asthma FR940405-1-00084 1 1141
aggravation FR940405-1-00084 1 1143
existing FR940405-1-00084 1 1145
cardiovascular FR940405-1-00084 1 1146
have FR940405-1-00084 1 1150
been FR940405-1-00084 1 1151
indicates FR940405-1-00084 1 1163
30 FR940405-1-00084 1 1168
office FR940405-1-00084 1 1171
having FR940405-1-00084 1 1178
environments FR940405-1-00084 1 1179
lead FR940405-1-00084 1 1182
unfortunately FR940405-1-00084 1 1190
quantitative FR940405-1-00084 1 1192
systematically FR940405-1-00084 1 1196
available FR940405-1-00084 1 1197
all FR940405-1-00084 1 1199
purposes FR940405-1-00084 2 1205 1277
evaluation FR940405-1-00084 2 1208 1280
explained FR940405-1-00084 1 1213
more FR940405-1-00084 1 1214
fully FR940405-1-00084 1 1215
assessment FR940405-1-00084 1 1219
discussion FR940405-1-00084 1 1220
has FR940405-1-00084 1 1224
primarily FR940405-1-00084 1 1225
focussed FR940405-1-00084 1 1226
upper FR940405-1-00084 2 1239 1247
respiratory FR940405-1-00084 2 1240 1248
symptoms FR940405-1-00084 2 1241 1249
headaches FR940405-1-00084 2 1244 1284
include FR940405-1-00084 1 1261
stuffy FR940405-1-00084 1 1262
nose FR940405-1-00084 3 1263 1266 1272
runny FR940405-1-00084 1 1265
dry FR940405-1-00084 1 1268
itchy FR940405-1-00084 1 1269
eyes FR940405-1-00084 1 1270
throat FR940405-1-00084 1 1274
our FR940405-1-00084 1 1279
defined FR940405-1-00084 1 1287
enough FR940405-1-00084 1 1291
require FR940405-1-00084 1 1293
medical FR940405-1-00084 1 1294
